Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
Top Cited Papers
- 19 April 2016
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 315 (15) , 1610-1623
- https://doi.org/10.1001/jama.2016.4218
Abstract
Research from JAMA — Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines — A Randomized Clinical TrialKeywords
This publication has 27 references indexed in Scilit:
- First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)The Journal of Infectious Diseases, 2012
- Postexposure antibody prophylaxis protects nonhuman primates from filovirus diseaseProceedings of the National Academy of Sciences, 2012
- Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccineJournal of Clinical Investigation, 2012
- International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populationsVaccine, 2011
- Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus ChallengeJournal of Virology, 2011
- The Th1 Immune Response toPlasmodium falciparumCircumsporozoite Protein Is Boosted by Adenovirus Vectors 35 and 26 with a Homologous InsertClinical and Vaccine Immunology, 2010
- Response definition criteria for ELISPOT assays revisitedCancer Immunology, Immunotherapy, 2010
- Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeysNature, 2008
- Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus MonkeysJournal of Virology, 2008
- Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and DJournal of Virology, 2007